Anavex Life Sciences Corp. (NASDAQ:AVXL) Investor Alert: Investigation Over Potential Wrongdoing

An investigation on behalf of investors in Anavex Life Sciences Corp. (NASDAQ:AVXL) shares over potential wrongdoing at Anavex Life Sciences Corp. was announced and NASDAQ:AVXL stockholders should contact the Shareholders Foundation.

San Diego, CA — (SBWIRE) — 03/21/2022 — An investigation on behalf of investors in shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) was announced over potential breaches of fiduciary duties by certain officers and directors at Anavex Life Sciences Corp.

Investors who purchased shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

The investigation by a law firm concerns whether certain Anavex Life Sciences directors breached their fiduciary duties and caused damage to the company and its shareholders.

New York based Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Anavex Life Sciences Corp. reported that its Total Revenue rose from $30.93 million for the 12 months period that ended on September 30, 2020, to $41.94 million for the 12 months period that ended on September 30, 2021, and that its Net Loss over those time periods increased from $26.28 million to $37.9 million.

Before the market opened on February 1, 2022, Anavex Life Sciences Corp. announced that a phase 3 trial of ANAVEX2-73 (blarcamesine) for Rett syndrome met primary and secondary endpoints. Following the announcement, several people on social media indicated that the primary and secondary endpoints were recently changed. STAT’s Adam Feuerstein tweeted, “Anavex changed the primary and secondary endpoints of this Rett study on Jan. 18, allowing it to claim success when the drug most likely failed.”

Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) declined from $19.83 per share in December 2021 to as low as $9.93 per share on February 4, 2022.

Those who purchased shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About The Shareholders Foundation
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit: http://www.sbwire.com/press-releases/anavex-life-sciences-corp-nasdaqavxl-investor-alert-investigation-1354904.htm

Media Relations Contact

Michael Daniels
Shareholders Foundation
Telephone: 1-858-779-1554
Email: Click to Email Michael Daniels
Web: https://www.shareholdersfoundation.com/